Study of Dextromethorphan in OCD and Related Disorders
Recruiting · NCT04899687 · Interventional (participants receive a specific treatment) · Lead sponsor: Stanford University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
- Living within California
- Capacity to provide informed consent
Exclusion criteria
- Current bipolar disorder or psychotic disorder
- Active moderate or severe substance use disorder, lifetime severe substance use disorder
- Pregnant or nursing women
- Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
- Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start
Where it is running
1 location listed across 1 US state.
- Stanford University - Stanford, California, United States